Name (Synonyms) | Correlation | |
---|---|---|
drug837 | Monitoring Visit - Week 8 Wiki | 1.00 |
drug835 | Monitoring Visit - Baseline Wiki | 1.00 |
drug1490 | Weekly Assessment Wiki | 1.00 |
drug836 | Monitoring Visit - Week 4 Wiki | 1.00 |
drug1419 | Treatment and prophylaxis Wiki | 1.00 |
drug600 | Hydroxychloroquine - Daily Dosing Wiki | 1.00 |
drug602 | Hydroxychloroquine - Weekly Dosing Wiki | 0.71 |
drug1035 | Placebo oral tablet Wiki | 0.20 |
Name (Synonyms) | Correlation | |
---|---|---|
D045169 | Severe Acute Respiratory Syndrome NIH | 0.06 |
D018352 | Coronavirus Infections NIH | 0.05 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The investigators plan to evaluate the efficacy of the 'test and treat' strategy of infected patients and prophylactic chloroquine treatment to all contacts. The strategy entails decentralized COVID-19 testing and starting chloroquine treatment immediately in all who are found to be infected. As viral loads decline to undetectable levels, the probability of onward transmission is reduced to very low levels. Such evaluation will require prospective surveillance to assess the population-level effect of transmission prevention.
Description: Incidence of secondary cases among contacts of a case and contacts of contacts
Measure: Effectiveness of chemoprophylaxis assessed by incidence of secondary COVID-19 cases Time: Up to 14 days after start of treatment